ER Y537S ER Y537S	Estrogen Receptor Positive Breast Cancer Estrogen Receptor Positive Breast Cancer	CDK6 inhibitor + GDC-9545 Sensitive: D – Preclinical J Med Chem - 3 weeks
HER-2 amplification HER-2 amplification	Hormone Receptor Positive Breast Cancer Hormone Receptor Positive Breast Cancer	Trazimera (trastuzumab biosimilar) Sensitive: A1 - Approval
HER-2 overexpression HER-2 overexpression	Hormone Receptor Positive Breast Cancer Hormone Receptor Positive Breast Cancer	Trazimera (trastuzumab biosimilar) Sensitive: A1 - Approval
HER-2 amplification HER-2 amplification	Hormone Receptor Positive Breast Cancer Hormone Receptor Positive Breast Cancer	Ontruzant (trastuzumab biosimilar) Sensitive: A1 - Approval
HER-2 overexpression HER-2 overexpression	Hormone Receptor Positive Breast Cancer Hormone Receptor Positive Breast Cancer	Ontruzant (trastuzumab biosimilar) Sensitive: A1 - Approval
HER-2 amplification HER-2 amplification	Hormone Receptor Positive Breast Cancer Hormone Receptor Positive Breast Cancer	Ogivri (trastuzumab biosimilar) Sensitive: A1 - Approval
HER-2 overexpression HER-2 overexpression	Hormone Receptor Positive Breast Cancer Hormone Receptor Positive Breast Cancer	Ogivri (trastuzumab biosimilar) Sensitive: A1 - Approval
HER-2 amplification HER-2 amplification	Hormone Receptor Positive Breast Cancer Hormone Receptor Positive Breast Cancer	Kanjinti (trastuzumab biosimilar) Sensitive: A1 - Approval
HER-2 overexpression HER-2 overexpression	Hormone Receptor Positive Breast Cancer Hormone Receptor Positive Breast Cancer	Kanjinti (trastuzumab biosimilar) Sensitive: A1 - Approval
HER-2 amplification HER-2 amplification	Hormone Receptor Positive Breast Cancer Hormone Receptor Positive Breast Cancer	Herzuma (trastuzumab biosimilar) Sensitive: A1 - Approval
HER-2 overexpression HER-2 overexpression	Hormone Receptor Positive Breast Cancer Hormone Receptor Positive Breast Cancer	Herzuma (trastuzumab biosimilar) Sensitive: A1 - Approval
HR positive HR positive	Hormone Receptor Positive Breast Cancer Hormone Receptor Positive Breast Cancer	ribociclib Sensitive: A1 - Approval
HER-2 overexpression HER-2 overexpression	Hormone Receptor Positive Breast Cancer Hormone Receptor Positive Breast Cancer	lapatinib Sensitive: A1 - Approval
ER positive ER positive	Estrogen Receptor Positive Breast Cancer Estrogen Receptor Positive Breast Cancer	fulvestrant Sensitive: A1 - Approval
HER-2 overexpression HER-2 overexpression	Hormone Receptor Positive Breast Cancer Hormone Receptor Positive Breast Cancer	neratinib Sensitive: A1 - Approval
HR positive HR positive	Hormone Receptor Positive Breast Cancer Hormone Receptor Positive Breast Cancer	olaparib Sensitive: A1 - Approval
HER-2 amplification HER-2 amplification	Hormone Receptor Positive Breast Cancer Hormone Receptor Positive Breast Cancer	neratinib Sensitive: A1 - Approval
ER positive ER positive	Estrogen Receptor Positive Breast Cancer Estrogen Receptor Positive Breast Cancer	exemestane Sensitive: A1 - Approval
HR positive HR positive	Hormone Receptor Positive Breast Cancer Hormone Receptor Positive Breast Cancer	letrozole Sensitive: A1 - Approval
HR positive HR positive	Hormone Receptor Positive Breast Cancer Hormone Receptor Positive Breast Cancer	anastrozole Sensitive: A1 - Approval
ER positive ER positive	Estrogen Receptor Positive Breast Cancer Estrogen Receptor Positive Breast Cancer	toremifene Sensitive: A1 - Approval
HR positive HR positive	Hormone Receptor Positive Breast Cancer Hormone Receptor Positive Breast Cancer	talazoparib Sensitive: A1 - Approval
HR positive HR positive	Hormone Receptor Positive Breast Cancer Hormone Receptor Positive Breast Cancer	fulvestrant Sensitive: A1 - Approval
HR positive HR positive	Hormone Receptor Positive Breast Cancer Hormone Receptor Positive Breast Cancer	palbociclib Resistant: A2 - Guideline
HR positive HR positive	Hormone Receptor Positive Breast Cancer Hormone Receptor Positive Breast Cancer	everolimus Sensitive: A2 - Guideline
HR positive HR positive	Hormone Receptor Positive Breast Cancer Hormone Receptor Positive Breast Cancer	Aromatase inhibitor + palbociclib Sensitive: A2 - Guideline
HR positive HR positive	Hormone Receptor Positive Breast Cancer Hormone Receptor Positive Breast Cancer	Aromatase inhibitor Sensitive: A2 - Guideline
HR positive HR positive	Hormone Receptor Positive Breast Cancer Hormone Receptor Positive Breast Cancer	trastuzumab + lapatinib Resistant: B - Late Trials
HR positive HR positive	Hormone Receptor Positive Breast Cancer Hormone Receptor Positive Breast Cancer	trastuzumab Resistant: B - Late Trials
HR positive HR positive	Hormone Receptor Positive Breast Cancer Hormone Receptor Positive Breast Cancer	lapatinib Resistant: B - Late Trials
CCNE1 overexpression CCNE1 overexpression	Hormone Receptor Positive Breast Cancer Hormone Receptor Positive Breast Cancer	palbociclib Resistant: B - Late Trials
ER mutation ER mutation	Estrogen Receptor Positive Breast Cancer Estrogen Receptor Positive Breast Cancer	palbociclib Sensitive: B - Late Trials
HR positive HR positive	Hormone Receptor Positive Breast Cancer Hormone Receptor Positive Breast Cancer	tamoxifen Sensitive: B - Late Trials
PLK1-H PLK1-H	Hormone Receptor Positive Breast Cancer Hormone Receptor Positive Breast Cancer	palbociclib Resistant: B - Late Trials
TP53 mutation TP53 mutation	Hormone Receptor Positive Breast Cancer Hormone Receptor Positive Breast Cancer	capecitabine Resistant: B - Late Trials
HR positive HR positive	Hormone Receptor Positive Breast Cancer Hormone Receptor Positive Breast Cancer	capecitabine Sensitive: B - Late Trials
BRCA1 mutation BRCA1 mutation	Hormone Receptor Positive Breast Cancer Hormone Receptor Positive Breast Cancer	ABT-888 Sensitive: B - Late Trials
HR positive HR positive	Hormone Receptor Positive Breast Cancer Hormone Receptor Positive Breast Cancer	palbociclib + abemaciclib Sensitive: B - Late Trials
HR positive HR positive	Hormone Receptor Positive Breast Cancer Hormone Receptor Positive Breast Cancer	alpelisib Sensitive: B - Late Trials
BRCA2 mutation BRCA2 mutation	Hormone Receptor Positive Breast Cancer Hormone Receptor Positive Breast Cancer	ABT-888 Sensitive: B - Late Trials
ER mutation ER mutation	Hormone Receptor Positive Breast Cancer Hormone Receptor Positive Breast Cancer	exemestane Resistant: B - Late Trials
ER mutation ER mutation	Estrogen Receptor Positive Breast Cancer Estrogen Receptor Positive Breast Cancer	fulvestrant Sensitive: B - Late Trials
ER mutation ER mutation	Estrogen Receptor Positive Breast Cancer Estrogen Receptor Positive Breast Cancer	exemestane Resistant: B - Late Trials
FGFR1 amplification FGFR1 amplification	Hormone Receptor Positive Breast Cancer Hormone Receptor Positive Breast Cancer	letrozole Resistant: B - Late Trials
ER rs2234693 ER rs2234693	Hormone Receptor Positive Breast Cancer Hormone Receptor Positive Breast Cancer	exemestane Sensitive: B - Late Trials
HSD17B2 overexpression HSD17B2 overexpression	Estrogen Receptor Positive Breast Cancer Estrogen Receptor Positive Breast Cancer	tamoxifen Sensitive: B - Late Trials
ER mutation ER mutation	Hormone Receptor Positive Breast Cancer Hormone Receptor Positive Breast Cancer	fulvestrant Sensitive: B - Late Trials
HR positive + HER-2 positive HR positive + HER-2 positive	Hormone Receptor Positive Breast Cancer Hormone Receptor Positive Breast Cancer	Aromatase inhibitor + trastuzumab + lapatinib Sensitive: B - Late Trials
BRCA1 mutation BRCA1 mutation	Hormone Receptor Positive Breast Cancer Hormone Receptor Positive Breast Cancer	talazoparib Sensitive: B - Late Trials
BRCA2 mutation BRCA2 mutation	Hormone Receptor Positive Breast Cancer Hormone Receptor Positive Breast Cancer	talazoparib Sensitive: B - Late Trials
HR positive HR positive	Hormone Receptor Positive Breast Cancer Hormone Receptor Positive Breast Cancer	abemaciclib Resistant: C1 - Off-label
PIK3CA mutation + HR positive PIK3CA mutation + HR positive	Hormone Receptor Positive Breast Cancer Hormone Receptor Positive Breast Cancer	alpelisib Sensitive: C1 - Off-label
ER positive ER positive	Estrogen Receptor Positive Breast Cancer Estrogen Receptor Positive Breast Cancer	Z-endoxifen hydrochloride Sensitive: C2 – Inclusion Criteria
HR positive HR positive	Hormone Receptor Positive Breast Cancer Hormone Receptor Positive Breast Cancer	trastuzumab + neratinib Sensitive: C2 – Inclusion Criteria
ER positive ER positive	Estrogen Receptor Positive Breast Cancer Estrogen Receptor Positive Breast Cancer	SAR439859 Sensitive: C2 – Inclusion Criteria
HER-2 mutation HER-2 mutation	Hormone Receptor Positive Breast Cancer Hormone Receptor Positive Breast Cancer	trastuzumab + neratinib Sensitive: C2 – Inclusion Criteria
HR positive HR positive	Hormone Receptor Positive Breast Cancer Hormone Receptor Positive Breast Cancer	enzalutamide Sensitive: C2 – Inclusion Criteria
CCND1 amplification CCND1 amplification	Estrogen Receptor Positive Breast Cancer Estrogen Receptor Positive Breast Cancer	palbociclib Resistant: C2 – Inclusion Criteria
ER-L ER-L	Estrogen Receptor Positive Breast Cancer Estrogen Receptor Positive Breast Cancer	palbociclib Resistant: C2 – Inclusion Criteria
ER positive ER positive	Estrogen Receptor Positive Breast Cancer Estrogen Receptor Positive Breast Cancer	alpelisib Sensitive: C2 – Inclusion Criteria
ER positive ER positive	Estrogen Receptor Positive Breast Cancer Estrogen Receptor Positive Breast Cancer	palbociclib Sensitive: C2 – Inclusion Criteria
PIK3CA mutation PIK3CA mutation	Hormone Receptor Positive Breast Cancer Hormone Receptor Positive Breast Cancer	alpelisib + fulvestrant Sensitive: C2 – Inclusion Criteria
ER positive ER positive	Estrogen Receptor Positive Breast Cancer Estrogen Receptor Positive Breast Cancer	tamoxifen Resistant: C2 – Inclusion Criteria
EPRS1 expression EPRS1 expression	Estrogen Receptor Positive Breast Cancer Estrogen Receptor Positive Breast Cancer	tamoxifen Sensitive: C3 – Early Trials
FTO expression FTO expression	Estrogen Receptor Positive Breast Cancer Estrogen Receptor Positive Breast Cancer	tamoxifen Sensitive: C3 – Early Trials
CTDSP1 expression CTDSP1 expression	Estrogen Receptor Positive Breast Cancer Estrogen Receptor Positive Breast Cancer	tamoxifen Sensitive: C3 – Early Trials
BIN3 expression BIN3 expression	Estrogen Receptor Positive Breast Cancer Estrogen Receptor Positive Breast Cancer	tamoxifen Sensitive: C3 – Early Trials
ER positive ER positive	Estrogen Receptor Positive Breast Cancer Estrogen Receptor Positive Breast Cancer	bevacizumab Sensitive: C3 – Early Trials
ER Y537S ER Y537S	Estrogen Receptor Positive Breast Cancer Estrogen Receptor Positive Breast Cancer	fulvestrant Sensitive: C3 – Early Trials
PIK3R1 mutation PIK3R1 mutation	Hormone Receptor Positive Breast Cancer Hormone Receptor Positive Breast Cancer	lenvatinib Resistant: C3 – Early Trials
CDK6 overexpression CDK6 overexpression	Estrogen Receptor Positive Breast Cancer Estrogen Receptor Positive Breast Cancer	fulvestrant Resistant: C3 – Early Trials
RSF1 amplification RSF1 amplification	Estrogen Receptor Positive Breast Cancer Estrogen Receptor Positive Breast Cancer	tamoxifen Resistant: C3 – Early Trials
USH2A mutation USH2A mutation	Hormone Receptor Positive Breast Cancer Hormone Receptor Positive Breast Cancer	lenvatinib Sensitive: C3 – Early Trials
NEFH mutation NEFH mutation	Hormone Receptor Positive Breast Cancer Hormone Receptor Positive Breast Cancer	lenvatinib Sensitive: C3 – Early Trials
APC mutation APC mutation	Hormone Receptor Positive Breast Cancer Hormone Receptor Positive Breast Cancer	lenvatinib Resistant: C3 – Early Trials
PTCH1 mutation PTCH1 mutation	Hormone Receptor Positive Breast Cancer Hormone Receptor Positive Breast Cancer	lenvatinib Sensitive: C3 – Early Trials
PALB2 mutation PALB2 mutation	Hormone Receptor Positive Breast Cancer Hormone Receptor Positive Breast Cancer	lenvatinib Resistant: C3 – Early Trials
NOS2 underexpression NOS2 underexpression	Estrogen Receptor Positive Breast Cancer Estrogen Receptor Positive Breast Cancer	tamoxifen Sensitive: C3 – Early Trials
TK1-H TK1-H	Hormone Receptor Positive Breast Cancer Hormone Receptor Positive Breast Cancer	fulvestrant + anastrozole Sensitive: C3 – Early Trials
HPGD underexpression HPGD underexpression	Estrogen Receptor Positive Breast Cancer Estrogen Receptor Positive Breast Cancer	tamoxifen Resistant: C3 – Early Trials
BRCA2 mutation BRCA2 mutation	Hormone Receptor Positive Breast Cancer Hormone Receptor Positive Breast Cancer	fulvestrant + anastrozole Resistant: C3 – Early Trials
BRCA1 mutation BRCA1 mutation	Hormone Receptor Positive Breast Cancer Hormone Receptor Positive Breast Cancer	fulvestrant + anastrozole Resistant: C3 – Early Trials
PIK3CA mutation PIK3CA mutation	Hormone Receptor Positive Breast Cancer Hormone Receptor Positive Breast Cancer	fulvestrant + anastrozole Sensitive: C3 – Early Trials
CCNE1 overexpression CCNE1 overexpression	Estrogen Receptor Positive Breast Cancer Estrogen Receptor Positive Breast Cancer	palbociclib Resistant: C3 – Early Trials
CDK2 overexpression CDK2 overexpression	Estrogen Receptor Positive Breast Cancer Estrogen Receptor Positive Breast Cancer	palbociclib Resistant: C3 – Early Trials
CCNE1-H CCNE1-H	Estrogen Receptor Positive Breast Cancer Estrogen Receptor Positive Breast Cancer	palbociclib Resistant: C3 – Early Trials
ER mutation ER mutation	Estrogen Receptor Positive Breast Cancer Estrogen Receptor Positive Breast Cancer	enobosarm Sensitive: C3 – Early Trials
HR positive HR positive	Hormone Receptor Positive Breast Cancer Hormone Receptor Positive Breast Cancer	pazopanib Sensitive: C3 – Early Trials
RB1 deletion RB1 deletion	Hormone Receptor Positive Breast Cancer Hormone Receptor Positive Breast Cancer	palbociclib Resistant: C3 – Early Trials
ER positive ER positive	Estrogen Receptor Positive Breast Cancer Estrogen Receptor Positive Breast Cancer	tamoxifen + TAK-228 Sensitive: C3 – Early Trials
CHID1 overexpression CHID1 overexpression	Hormone Receptor Positive Breast Cancer Hormone Receptor Positive Breast Cancer	tamoxifen Resistant: C3 – Early Trials
AKT1 overexpression AKT1 overexpression	Hormone Receptor Positive Breast Cancer Hormone Receptor Positive Breast Cancer	tamoxifen Resistant: C3 – Early Trials
76-gene signature 76-gene signature	Estrogen Receptor Positive Breast Cancer Estrogen Receptor Positive Breast Cancer	tamoxifen Sensitive: C3 – Early Trials

Hormone Receptor Positive Breast Cancer

Associations(195)

Associations
(195)